FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024983650> ?p ?o ?g. }

• W2024983650 endingPage "788" @default.
• W2024983650 startingPage "784" @default.
• W2024983650 abstract "ABSTRACT Racial differences in antiretroviral treatment responses remain incompletely explained and may be a consequence of differential pharmacokinetics (PK) associated with race. Raltegravir, an inhibitor of HIV-1 integrase, is commonly used in the treatment of HIV-infected patients, many of whom are African-American. However, there are few data regarding the PK of raltegravir in African-Americans. HIV-infected men and women, self-described as African-American and naive to antiretroviral therapy were treated with raltegravir (RAL) at 400 mg twice a day, plus a fixed dose of tenofovir-emtricitabine (TDF/FTC) at 300 mg/200 mg once daily. Intensive PK sampling was conducted over 24 h at week 4. Drug concentrations at two trough values of 12 and 24 h after dosing ( C 12 and C 24 ), area under the concentration-curve values (AUC), maximum drug concentration ( C max ), and the time at which this concentration occurred ( T max ) in plasma were estimated with noncompartmental pharmacokinetic methods and compared to data from a subset of white subjects randomized to the RAL twice a day (plus TDF/FTC) arm of the QDMRK study, a phase III study of the safety and efficacy of once daily versus twice daily RAL in treatment naive patients. A total of 38 African-American participants were enrolled (90% male) into the REAL cohort with the following median baseline characteristics: age of 36 years, body mass index (BMI) of 23 kg/m 2 , and a CD4 cell count of 339/ml. Plasma HIV RNA levels were below 200 copies/ml in 95% of participants at week 4. The characteristics of the 16 white QDMRK study participants were similar, although fewer (69%) were male, the median age was higher (45 years), and BMI was lower (19 kg/m 2 ). There was considerable interindividual variability in RAL concentrations in both cohorts. Median C 12 in REAL was 91 ng/ml (range, 10 to 1,386) and in QDMRK participants was 128 ng/ml (range, 15 to 1,074). The C max median concentration was 1,042 ng/ml (range, 196 to 10,092) for REAL and 1,360 ng/ml (range, 218 to 9,701) for QDMRK. There were no significant differences in any RAL PK parameter between these cohorts of African-American and white individuals. Based on plasma PK, and with similar adherence rates, the performance of RAL among HIV-infected African-Americans should be no different than that of infected patients who are white." @default.
• W2024983650 created "2016-06-24" @default.
• W2024983650 creator A5010371161 @default.
• W2024983650 creator A5021388560 @default.
• W2024983650 creator A5024560316 @default.
• W2024983650 creator A5032707485 @default.
• W2024983650 creator A5034242048 @default.
• W2024983650 creator A5041306934 @default.
• W2024983650 creator A5044836509 @default.
• W2024983650 creator A5046294611 @default.
• W2024983650 creator A5053291102 @default.
• W2024983650 creator A5060710888 @default.
• W2024983650 creator A5073736310 @default.
• W2024983650 creator A5078111251 @default.
• W2024983650 creator A5090548199 @default.
• W2024983650 date "2013-02-01" @default.
• W2024983650 modified "2023-10-16" @default.
• W2024983650 title "Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study" @default.
• W2024983650 cites W1999245218 @default.
• W2024983650 cites W2001435229 @default.
• W2024983650 cites W2007755993 @default.
• W2024983650 cites W2008324241 @default.
• W2024983650 cites W2016258101 @default.
• W2024983650 cites W2038275061 @default.
• W2024983650 cites W2041925939 @default.
• W2024983650 cites W2056596520 @default.
• W2024983650 cites W2068738256 @default.
• W2024983650 cites W2073828800 @default.
• W2024983650 cites W2075531822 @default.
• W2024983650 cites W2087005825 @default.
• W2024983650 cites W2088666904 @default.
• W2024983650 cites W2090938082 @default.
• W2024983650 cites W2150504993 @default.
• W2024983650 cites W2157533742 @default.
• W2024983650 cites W2161993838 @default.
• W2024983650 cites W2179430089 @default.
• W2024983650 doi "https://doi.org/10.1128/aac.01826-12" @default.
• W2024983650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3553727" @default.
• W2024983650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23183440" @default.
• W2024983650 hasPublicationYear "2013" @default.
• W2024983650 type Work @default.
• W2024983650 sameAs 2024983650 @default.
• W2024983650 citedByCount "14" @default.
• W2024983650 countsByYear W20249836502013 @default.
• W2024983650 countsByYear W20249836502014 @default.
• W2024983650 countsByYear W20249836502015 @default.
• W2024983650 countsByYear W20249836502016 @default.
• W2024983650 countsByYear W20249836502017 @default.
• W2024983650 countsByYear W20249836502018 @default.
• W2024983650 countsByYear W20249836502019 @default.
• W2024983650 countsByYear W20249836502020 @default.
• W2024983650 crossrefType "journal-article" @default.
• W2024983650 hasAuthorship W2024983650A5010371161 @default.
• W2024983650 hasAuthorship W2024983650A5021388560 @default.
• W2024983650 hasAuthorship W2024983650A5024560316 @default.
• W2024983650 hasAuthorship W2024983650A5032707485 @default.
• W2024983650 hasAuthorship W2024983650A5034242048 @default.
• W2024983650 hasAuthorship W2024983650A5041306934 @default.
• W2024983650 hasAuthorship W2024983650A5044836509 @default.
• W2024983650 hasAuthorship W2024983650A5046294611 @default.
• W2024983650 hasAuthorship W2024983650A5053291102 @default.
• W2024983650 hasAuthorship W2024983650A5060710888 @default.
• W2024983650 hasAuthorship W2024983650A5073736310 @default.
• W2024983650 hasAuthorship W2024983650A5078111251 @default.
• W2024983650 hasAuthorship W2024983650A5090548199 @default.
• W2024983650 hasBestOaLocation W20249836501 @default.
• W2024983650 hasConcept C112705442 @default.
• W2024983650 hasConcept C126322002 @default.
• W2024983650 hasConcept C142462285 @default.
• W2024983650 hasConcept C203014093 @default.
• W2024983650 hasConcept C2777288759 @default.
• W2024983650 hasConcept C2777302000 @default.
• W2024983650 hasConcept C2779778239 @default.
• W2024983650 hasConcept C2780404665 @default.
• W2024983650 hasConcept C2988731192 @default.
• W2024983650 hasConcept C2993143319 @default.
• W2024983650 hasConcept C3013748606 @default.
• W2024983650 hasConcept C71924100 @default.
• W2024983650 hasConcept C98274493 @default.
• W2024983650 hasConceptScore W2024983650C112705442 @default.
• W2024983650 hasConceptScore W2024983650C126322002 @default.
• W2024983650 hasConceptScore W2024983650C142462285 @default.
• W2024983650 hasConceptScore W2024983650C203014093 @default.
• W2024983650 hasConceptScore W2024983650C2777288759 @default.
• W2024983650 hasConceptScore W2024983650C2777302000 @default.
• W2024983650 hasConceptScore W2024983650C2779778239 @default.
• W2024983650 hasConceptScore W2024983650C2780404665 @default.
• W2024983650 hasConceptScore W2024983650C2988731192 @default.
• W2024983650 hasConceptScore W2024983650C2993143319 @default.
• W2024983650 hasConceptScore W2024983650C3013748606 @default.
• W2024983650 hasConceptScore W2024983650C71924100 @default.
• W2024983650 hasConceptScore W2024983650C98274493 @default.
• W2024983650 hasIssue "2" @default.
• W2024983650 hasLocation W20249836501 @default.
• W2024983650 hasLocation W20249836502 @default.
• W2024983650 hasLocation W20249836503 @default.
• W2024983650 hasLocation W20249836504 @default.
• W2024983650 hasLocation W20249836505 @default.

• next